As device therapy continues to evolve, there is an emerging opportunity to address tricuspid valve disease in patients who previously were overlooked due to their high surgical risk. Proper patient selection and medical optimization will be critical factors driving the success or failure of these nascent technologies. 

 In this interview, Sean Pinney MD, FACC, FAST, FHFSA, and Sidney C. Smith Jr. MD, MACC, discuss "Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?"

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL